Sign Up
Stories
Promising Trials for Post-COVID-19 and Graft-Versus-Host Disease
Share
Advancements in Cancer Treatment and Mar...
Advancements in Medical Research
Advancements in Medical Trials
Rare Gastrointestinal Diseases Market Ex...
Rituximab Biosimilars Market Growth
Seres Therapeutics' Microbiome Therapeut...
Overview
API
Biopharmaceutical companies GeNeuro and MaaT Pharma present promising results for their clinical trials involving treatments for post-COVID-19 symptoms and graft-versus-host disease, respectively.
Ask a question
How might the continued trial of temelimab impact the treatment landscape for post-COVID-19 symptoms?
In what ways could the advancements in these clinical trials influence the future direction of biopharmaceutical research and development?
What are the potential implications of MaaT Pharma's positive results for the broader field of Microbiome Therapies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage